IOVA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 12.10%

Insider Buying (Last 12 Months): $2,287,500.00

Insider Selling (Last 12 Months): $503,000.00

Iovance Biotherapeutics Insider Trading History Chart

Iovance Biotherapeutics Share Price & Price History

^$7.81

▼ -0.03 (-0.38%)

As of 12/17/2024 06:56 PM ET

Days: 30 | 90 | 365

Trump’s Secret Manhattan Project

From Banyan Hill Publishing | Ad

On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.

Click here and I’ll show you exactly how to position your money

Iovance Biotherapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/12/2024	Ryan D Maynard	Director	Sell	50,000	$10.06	$503,000.00	7,500
2/20/2024	Merrill A Mcpeak	Director	Buy	250,000	$9.15	$2,287,500.00	320,150
9/18/2023	Merrill A Mcpeak	Director	Buy	10,000	$5.56	$55,600.00	248,633
9/15/2023	Wayne P. Rothbaum	Director	Buy	5,000,000	$5.30	$26,500,000.00	23,067,333
12/21/2022	Merrill A Mcpeak	Director	Buy	10,000	$6.15	$61,500.00	70,150
12/2/2022	Wayne P. Rothbaum	Director	Buy	10,000,000	$6.50	$65,000,000.00	18,067,333
11/28/2022	Frederick G. Vogt	CEO	Buy	1,000	$5.98	$5,980.00	2,000
11/28/2022	Merrill A Mcpeak	Director	Buy	10,000	$6.18	$61,800.00	228,633
11/23/2022	Iain D. Dukes	Director	Buy	10,000	$6.10	$61,000.00	22,000
6/1/2022	Frederick G. Vogt	CEO	Buy	1,000	$6.44	$6,440.00	1,000
5/31/2022	Merrill A Mcpeak	Director	Buy	10,000	$6.84	$68,400.00	20,150

Is Starlink Set For The Largest IPO In History?

From Paradigm Press | Ad

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!

Click here now for the urgent details.

SEC Filings (Institutional Ownership Changes) for Iovance Biotherapeutics (NASDAQ:IOVA)

77.03% of Iovance Biotherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Iovance Biotherapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/27/2024	Franklin Resources Inc.	100,229	$0.98M	0.0%	+9.2%	0.033%
11/21/2024	SkyView Investment Advisors LLC	20,000	$0.19M	0.0%	N/A	0.007%
11/18/2024	Arete Wealth Advisors LLC	34,600	$0.33M	0.0%	-45.4%	0.011%
11/16/2024	Geode Capital Management LLC	5,648,995	$53.05M	0.0%	-2.4%	1.853%
11/15/2024	Barclays PLC	604,584	$5.68M	0.0%	+118.8%	0.198%
11/15/2024	Wellington Management Group LLP	129,482	$1.22M	0.0%	+10.3%	0.042%
11/15/2024	State Street Corp	13,201,978	$123.97M	0.0%	+4.6%	4.332%
11/15/2024	Stifel Financial Corp	223,107	$2.10M	0.0%	+35.8%	0.073%
11/15/2024	NFJ Investment Group LLC	189,655	$1.78M	0.1%	-4.4%	0.062%
11/15/2024	Centiva Capital LP	16,625	$0.16M	0.0%	N/A	0.005%
11/15/2024	Erste Asset Management GmbH	34,000	$0.33M	0.0%	N/A	0.011%
11/14/2024	PFM Health Sciences LP	132,152	$1.24M	0.1%	-13.5%	0.043%
11/14/2024	Portland Investment Counsel Inc.	40,000	$0.38M	0.1%	+33.3%	0.013%
11/14/2024	Braidwell LP	217,928	$2.05M	0.1%	-85.1%	0.072%
11/14/2024	Verition Fund Management LLC	23,679	$0.22M	0.0%	N/A	0.008%
11/14/2024	Captrust Financial Advisors	49,606	$0.47M	0.0%	+95.0%	0.016%
11/14/2024	Walleye Capital LLC	13,665	$0.13M	0.0%	-45.6%	0.004%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	1,946,842	$18.28M	0.0%	-2.4%	0.639%
11/13/2024	BNP Paribas Financial Markets	113,724	$1.07M	0.0%	-75.5%	0.037%
11/13/2024	FMR LLC	82,662	$0.78M	0.0%	+79.2%	0.027%
11/13/2024	The Manufacturers Life Insurance Company	311,907	$2.93M	0.0%	-7.0%	0.102%
11/13/2024	DRW Securities LLC	12,854	$0.12M	0.0%	N/A	0.004%
11/12/2024	Pekin Hardy Strauss Inc.	33,050	$0.31M	0.0%	-5.7%	0.012%
11/12/2024	Algert Global LLC	54,070	$0.51M	0.0%	+53.2%	0.019%
11/12/2024	Eagle Asset Management Inc.	1,356,779	$12.74M	0.1%	-30.0%	0.485%
11/12/2024	Charles Schwab Investment Management Inc.	1,913,144	$17.96M	0.0%	-3.6%	0.684%
11/9/2024	Landscape Capital Management L.L.C.	65,525	$0.62M	0.1%	N/A	0.023%
11/9/2024	Intech Investment Management LLC	97,958	$0.92M	0.0%	N/A	0.035%
11/8/2024	Grandfield & Dodd LLC	30,070	$0.28M	0.0%	N/A	0.011%
11/7/2024	LMR Partners LLP	41,211	$0.39M	0.0%	-32.7%	0.015%
11/7/2024	Quest Partners LLC	2,819	$26K	0.0%	-43.7%	0.001%
11/6/2024	Curi RMB Capital LLC	108,637	$1.02M	0.0%	+49.8%	0.039%
11/6/2024	Pier 88 Investment Partners LLC	44,180	$0.42M	0.1%	-24.6%	0.016%
11/6/2024	Saturna Capital Corp	20,553	$0.19M	0.0%	+7.0%	0.007%
11/5/2024	Victory Capital Management Inc.	144,280	$1.36M	0.0%	+399.4%	0.052%
11/5/2024	GSA Capital Partners LLP	25,824	$0.24M	0.0%	N/A	0.009%
11/4/2024	Los Angeles Capital Management LLC	61,759	$0.58M	0.0%	+156.0%	0.022%
11/2/2024	XML Financial LLC	14,500	$0.14M	0.0%	+7.4%	0.005%
11/1/2024	Assetmark Inc.	12,853	$0.12M	0.0%	+48.0%	0.005%
10/31/2024	Principal Financial Group Inc.	4,033,184	$37.87M	0.0%	+59.0%	1.441%
10/30/2024	Beacon Financial Advisory LLC	21,120	$0.20M	0.1%	+42.7%	0.008%
10/29/2024	Farther Finance Advisors LLC	15,389	$0.15M	0.0%	+142.3%	0.005%
10/28/2024	Creative Financial Designs Inc. ADV	21,740	$0.20M	0.0%	+59.3%	0.008%
10/28/2024	Rice Hall James & Associates LLC	1,679,157	$15.77M	0.9%	+2.6%	0.600%
10/28/2024	US Bancorp DE	19,655	$0.19M	0.0%	-30.9%	0.007%
10/25/2024	China Universal Asset Management Co. Ltd.	58,376	$0.55M	0.1%	+77.6%	0.021%
10/24/2024	Clear Harbor Asset Management LLC	17,550	$0.17M	0.0%	-43.0%	0.006%
10/23/2024	Mirae Asset Global Investments Co. Ltd.	10,978	$0.11M	0.0%	+31.4%	0.004%
10/23/2024	Hennion & Walsh Asset Management Inc.	351,449	$3.30M	0.2%	-4.5%	0.126%
10/22/2024	Bank Pictet & Cie Europe AG	19,368	$0.18M	0.0%	-54.9%	0.007%
10/16/2024	nVerses Capital LLC	15,800	$0.15M	0.1%	N/A	0.006%
10/16/2024	Vontobel Holding Ltd.	18,940	$0.18M	0.0%	+32.5%	0.007%
10/16/2024	SeaCrest Wealth Management LLC	20,406	$0.19M	0.0%	-5.9%	0.007%
10/11/2024	Creative Planning	73,489	$0.69M	0.0%	+2.6%	0.026%
10/11/2024	ORG Wealth Partners LLC	9,432	$89K	0.0%	N/A	0.003%
10/10/2024	Shaker Investments LLC OH	100,712	$0.95M	0.4%	+27.7%	0.036%
10/10/2024	Exchange Traded Concepts LLC	17,071	$0.16M	0.0%	+11.6%	0.006%
10/8/2024	Brookstone Capital Management	20,055	$0.19M	0.0%	+43.9%	0.007%
10/5/2024	Handelsbanken Fonder AB	74,800	$0.70M	0.0%	+18.2%	0.027%
8/19/2024	B. Riley Wealth Advisors Inc.	13,296	$0.11M	0.0%	N/A	0.005%
8/16/2024	Perceptive Advisors LLC	25,933,142	$207.98M	4.9%	+34.6%	9.267%
8/16/2024	Creative Planning	71,593	$0.57M	0.0%	-7.1%	0.026%
8/16/2024	Algert Global LLC	35,286	$0.28M	0.0%	-9.0%	0.013%
8/16/2024	Cim Investment Management Inc.	31,172	$0.25M	0.1%	+126.3%	0.011%
8/15/2024	Long Focus Capital Management LLC	4,132,000	$33.14M	1.3%	+195.1%	1.477%
8/15/2024	The Manufacturers Life Insurance Company	335,513	$2.69M	0.0%	-6.5%	0.120%
8/15/2024	Dark Forest Capital Management LP	44,858	$0.36M	0.1%	N/A	0.016%
8/15/2024	AQR Capital Management LLC	11,477	$92K	0.0%	-71.3%	0.004%
8/14/2024	Squarepoint Ops LLC	257,543	$2.07M	0.0%	N/A	0.092%
8/14/2024	Marshall Wace LLP	1,612,055	$12.93M	0.0%	N/A	0.576%
8/14/2024	Xponance Inc.	16,279	$0.13M	0.0%	+13.0%	0.006%
8/14/2024	Magnetar Financial LLC	82,363	$0.66M	0.0%	N/A	0.029%
8/14/2024	Hood River Capital Management LLC	2,732,427	$21.91M	0.5%	+4.1%	0.976%
8/14/2024	EverSource Wealth Advisors LLC	6,609	$58K	0.0%	N/A	0.002%
8/14/2024	ProShare Advisors LLC	49,061	$0.39M	0.0%	-21.1%	0.018%
8/14/2024	Profund Advisors LLC	124,660	$1M	0.0%	+33.1%	0.045%
8/13/2024	Ensign Peak Advisors Inc	74,592	$0.60M	0.0%	+13.4%	0.027%
8/13/2024	Sei Investments Co.	284,761	$2.28M	0.0%	-14.5%	0.102%
8/12/2024	Seven Eight Capital LP	77,240	$0.62M	0.1%	-55.7%	0.028%
8/12/2024	Vanguard Personalized Indexing Management LLC	22,085	$0.18M	0.0%	+27.2%	0.008%
8/12/2024	E Fund Management Co. Ltd.	40,912	$0.33M	0.0%	+48.2%	0.015%
8/10/2024	Virtu Financial LLC	94,099	$0.76M	0.1%	N/A	0.034%
8/9/2024	Edgestream Partners L.P.	99,605	$0.80M	0.0%	N/A	0.036%
8/9/2024	Pekin Hardy Strauss Inc.	35,050	$0.28M	0.0%	-18.6%	0.013%
8/9/2024	Dimensional Fund Advisors LP	2,265,555	$18.17M	0.0%	-21.1%	0.810%
8/8/2024	Wealthspire Advisors LLC	57,000	$0.46M	0.0%	N/A	0.020%
8/8/2024	Parametrica Management Ltd	261,090	$2.09M	2.8%	+98.4%	0.093%
8/8/2024	American Century Companies Inc.	203,038	$1.63M	0.0%	-40.0%	0.073%
8/8/2024	Rice Hall James & Associates LLC	1,636,025	$13.12M	0.8%	-4.5%	0.585%
8/7/2024	Headlands Technologies LLC	16,067	$0.13M	0.0%	N/A	0.006%
8/7/2024	Daiwa Securities Group Inc.	8,813	$71K	0.0%	+754.0%	0.003%
8/7/2024	Choreo LLC	14,354	$0.12M	0.0%	N/A	0.005%
8/6/2024	Quest Partners LLC	5,003	$40K	0.0%	+1,237.7%	0.002%
8/6/2024	Pier 88 Investment Partners LLC	58,580	$0.47M	0.1%	+155.8%	0.021%
8/6/2024	Los Angeles Capital Management LLC	24,124	$0.19M	0.0%	N/A	0.009%
8/6/2024	Candriam S.C.A.	500,033	$4.01M	0.0%	-52.8%	0.179%
8/5/2024	Arizona State Retirement System	54,734	$0.44M	0.0%	+3.8%	0.020%
8/3/2024	TD Asset Management Inc	284,878	$2.29M	0.0%	-43.6%	0.102%
8/1/2024	Rhumbline Advisers	368,800	$2.96M	0.0%	-5.8%	0.132%
7/31/2024	Abacus Planning Group Inc.	10,284	$82K	0.0%	N/A	0.004%

Data available starting January 2016

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Today's Range

Now: $7.81

$7.64

$7.85

50 Day Range

MA: $9.58

$7.83

$12.28

52 Week Range

Now: $7.81

$6.70

$18.33

Volume

4,266,305 shs

Average Volume

7,169,563 shs

Market Capitalization

$2.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

Who are the company insiders with the largest holdings of Iovance Biotherapeutics?: Iovance Biotherapeutics' top insider shareholders include:
Wayne P Rothbaum (Director)
Merrill A Mcpeak (Director)
Ryan D Maynard (Director)
Learn More about top insider investors at Iovance Biotherapeutics.
Who are the major institutional investors of Iovance Biotherapeutics?: Iovance Biotherapeutics' top institutional shareholders include:
State Street Corp — 4.33%
Geode Capital Management LLC — 1.85%
Principal Financial Group Inc. — 1.44%
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC — 0.64%
Charles Schwab Investment Management Inc. — 0.68%
Rice Hall James & Associates LLC — 0.60%
Learn More about top institutional investors of Iovance Biotherapeutics stock.
Which major investors are selling Iovance Biotherapeutics stock?: During the last quarter, IOVA stock was sold by these institutional investors:
Braidwell LP
Eagle Asset Management Inc.
BNP Paribas Financial Markets
Geode Capital Management LLC
Charles Schwab Investment Management Inc.
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
Arete Wealth Advisors LLC
The Manufacturers Life Insurance Company
Which major investors are buying Iovance Biotherapeutics stock?: During the last quarter, IOVA stock was acquired by institutional investors including:
Principal Financial Group Inc.
State Street Corp
Barclays PLC
Victory Capital Management Inc.
Intech Investment Management LLC
Jane Street Group LLC
Landscape Capital Management L.L.C.
Stifel Financial Corp
Within the last year, these company insiders have bought Iovance Biotherapeutics stock:
Wayne P Rothbaum (Director)
Merrill A Mcpeak (Director)
Learn More investors buying Iovance Biotherapeutics stock.